We are pleased to announce that the CKB public token sale will take place on CoinList, and will open for registration and KYC process on the 1st of October, with the official sale starting on the 16th of October. With the current timeline we have been able to structure the offering to allow accredited US residents to participate.
The sale will last for 2 weeks or end 48 hours after allocation reached.
Visit our CoinList page to sign up for an account prior to the sale.
For more details about the public sale, including token supply, public sale price, and other pertinent information, please refer to our previous announcement.
Since launching the Nervos project at the start of 2018, the team has worked tirelessly to build what we believe to be the leading blockchain solution for the foundation of the decentralized economy. The core of the Network is the Common Knowledge Base (CKB) — the layer 1, store of value, public blockchain protocol of Nervos.For more information about the Nervos Network and Common Knowledge Base, please visit our website. To stay up to date on future announcements please sign up to our mailing list.
PLEASE BE AWARE: Nervos Foundation is not responsible for, has not approved, and has not been involved in any pre-trading, funding pools or reselling of Nervos CKByte tokens. Any and all the details of the Nervos public sale will be announced through our official website, official social channels and should be the sole source of information. PLEASE DO NOT RELY ON ANY OTHER SOURCES OF INFORMATION. Please ensure extreme care and due diligence in all matters regarding token purchasing and ownership. The Nervos Foundation is not responsible or liable for any loss of funds or other issues arising from actions taken by third parties, bad actors or your negligence.
The offer and sale of the Nervos CKB has not been registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”) or under the securities laws of any state or foreign jurisdiction. This offering is being made (1) inside the United States only to “accredited investors” (as defined in Section 501 of the Securities Act) in reliance on Regulation D under the Securities Act, and (2) outside the United States to non-U.S. persons (as defined in Section 902 of Regulation S under the Securities Act) (and only in jurisdictions where such offer and sale is permitted under applicable law) in reliance on Regulation S under the Securities Act. The Nervos CKB may not be transferred, pledged or hypothecated except as permitted under the Securities Act and applicable state and foreign securities laws pursuant to an effective registration statement or an exemption therefrom. Your participation, if any, in the Public Sale are subject to the terms of sale set forth in connection with such sale. This announcement is provided for informational purposes only and does not guarantee anyone a right to participate in the Public Sale.
The Nervos Public Sale and all associated events and activities are not and will not be offered or sold, directly or indirectly, to any natural person, legal person, unincorporated organization or any other entity within the People’s Republic of China (for such purposes, not including the Hong Kong and Macau special administrative regions and Taiwan), South Korea and Japan.
Also, we are not offering the Public Sale in any country subject to OFAC sanctions (Belarus, Burma, Cote D’Ivoire, Cuba, Democratic Republic of Congo, Iran, Iraq, Liberia, North Korea, Sudan, Syria, and Zimbabwe) and Central African Republic, Crimea, Lebanon, Libya, Somalia, South Sudan, Venezuela and Yemen.
Nervos Foundation reserves the right to change or modify any of the terms of the Public Sale set forth herein at any time.